Vitamin D

Vitamin D is less a vitamin than a secosteroid hormone. The skin synthesizes cholecalciferol (D3) from 7-dehydrocholesterol on UVB exposure; the diet contributes modestly (oily fish, fortified foods, and ergocalciferol/D2 from some plant sources). Both forms are hydroxylated in the liver to 25-hydroxyvitamin D [25(OH)D] — the storage form measured clinically — and then to the active hormone 1,25-dihydroxyvitamin D (calcitriol) in the kidney and, importantly for neuropsychiatry, locally within the brain. Calcitriol acts through the nuclear vitamin D receptor (VDR), a transcription factor that regulates hundreds of genes.

Vitamin D's claim on psychiatry rests on three pillars: VDRs are distributed throughout mood-relevant brain regions; deficiency is epidemiologically associated with depression; and supplementation trials show benefit — but, as with omega-3, the benefit is real, heterogeneous, and almost entirely conditional on baseline status. Vitamin D is the cleanest example in this series of a supplement that treats a deficiency rather than a disease.

Proposed Mechanism

VDRs and the activating enzyme 1α-hydroxylase are expressed in the hippocampus, hypothalamus, substantia nigra, and prefrontal cortex — regions central to mood, reward, and stress regulation. Through these receptors, vitamin D plausibly influences mood by several routes:

• Neurotrophic regulation. Calcitriol upregulates neurotrophins including NGF, GDNF, and (in preclinical models) BDNF, feeding the neuroplasticity common pathway.
• Monoamine synthesis. Vitamin D response elements have been identified in the promoter region of tryptophan hydroxylase 2, the brain isoform that synthesizes serotonin; vitamin D may thus help set central serotonergic tone.
• Immunomodulation. Vitamin D is broadly anti-inflammatory, dampening pro-inflammatory cytokine production.
• Neurosteroid and calcium-homeostatic effects, plus protection against oxidative injury.

The mechanistic story also offers a tidy account of seasonal affective disorder: reduced winter UVB lowers cutaneous synthesis, plausibly contributing to seasonal mood worsening — though light's effects on circadian and serotonergic systems are at least as important, and vitamin D supplementation has not reliably outperformed light therapy for SAD.

Evidence Base

The vitamin D literature is large, heterogeneous, and — read carelessly — contradictory. Read carefully, it tells a consistent conditional story.

The meta-analytic signal. Pooled RCT estimates for vitamin D on depressive symptoms cluster in the small-to-moderate range, with several recent meta-analyses reporting SMDs around −0.36 to −0.40; umbrella analyses concur (Musazadeh 2022, SMD ≈ −0.40), and observational data link low 25(OH)D to higher depression odds (OR ≈ 1.6). Dose–response analyses suggest larger effects at higher doses (>2,800 IU/day) and durations ≥8 weeks.

The crucial moderators. The effect is concentrated in two conditions: baseline deficiency and clinically significant depression at entry. Trials enrolling vitamin-D–replete or non-depressed participants tend toward null. The decisive negative datapoint is the depression arm of the large VITAL trial (VITAL-DEP; Okereke et al., 2020): in nearly 18,000 generally vitamin-D–sufficient older adults, 2,000 IU/day of D3 did not prevent depression or improve mood over roughly five years. Paired with the negative VITAL-DEP omega-3 result, this is the field's strongest evidence that supplementing the replete, well population does not prevent mood disorder.

The honest synthesis, almost identical in shape to omega-3: vitamin D corrects a deficiency-linked contributor to low mood and modestly improves depressive symptoms in deficient and/or depressed patients, with little to offer the replete and no demonstrated preventive role in unselected populations. The wide spread of reported effect sizes is largely explained by whether a given trial enrolled the people the mechanism predicts will respond.

Who Might Benefit / Indications

The strongest case is the depressed patient with measured 25(OH)D deficiency or insufficiency — here, repletion is sound general medicine with a plausible mood dividend. Vitamin D is a reasonable adjunct in depressed patients with deficiency, particularly with somatic comorbidity, limited sun exposure, higher latitude, darker skin, obesity (vitamin D is sequestered in adipose tissue), or malabsorption. It is also reasonable to check and correct in seasonal presentations. It is not indicated to prevent depression in replete individuals, and it is not a substitute for first-line antidepressant treatment in moderate-to-severe illness.

A practical principle this supplement makes vivid: measure, then treat. Vitamin D is one of the few nutraceuticals in this series with a cheap, validated status biomarker; using it converts a blind supplement into a targeted repletion.

Formulation, Dosing & Bioavailability

Cholecalciferol (D3) is preferred over ergocalciferol (D2); D3 raises and sustains serum 25(OH)D more effectively. Repletion regimens are individualized to baseline level and body habitus; commonly 1,000–4,000 IU/day for maintenance/repletion, with higher short-course or weekly loading (e.g., 50,000 IU weekly) reserved for documented deficiency under monitoring. Vitamin D is fat-soluble — take with a fat-containing meal to optimize absorption. Because it is stored and slowly cleared, the clinical and biochemical response lags by weeks; recheck 25(OH)D after ~8–12 weeks of repletion. Adequacy is usually defined as 25(OH)D ≥ 20 ng/mL (50 nmol/L), with many advocating ≥30 ng/mL, though optimal targets for mood specifically are not established.

Safety & Interactions

Vitamin D is safe within standard dosing. The principal hazard is hypercalcemia from excessive supplementation — relevant only at sustained very high intakes (generally well above 4,000 IU/day) or with predisposing conditions (granulomatous disease, primary hyperparathyroidism). Symptoms of toxicity track hypercalcemia: nausea, polyuria, confusion, and, chronically, nephrolithiasis and vascular calcification. Routine doses do not cause this. Interactions are few; thiazide diuretics can raise calcium (additive with vitamin D), and certain anticonvulsants and glucocorticoids accelerate vitamin D catabolism, raising requirements. Vitamin D does not interact pharmacokinetically with antidepressants.

Convergence

Vitamin D threads through the same mechanisms as the rest of the series: neurotrophic support, serotonergic enabling, and immunomodulation. Its seasonal angle links to circadian and light-based accounts. Within this series it is the paradigm "deficiency-correction" agent, sharing that logic and its measure-then-treat discipline with the one-carbon (methylation) cluster and magnesium and zinc, and its deficiency-conditional, prevention-negative trial pattern with omega-3.

Caveats

Vitamin D research is heavily confounded by reverse causation and the "sick-quitter" problem: depressed, ill, and inactive people get less sun and lower vitamin D, so low 25(OH)D is partly a consequence of poor health and depression rather than a cause. This inflates observational associations and complicates causal claims. The very wide range of meta-analytic effect sizes is not contradictory once moderators are accounted for — but it does mean headline numbers should never be quoted without the baseline-status and severity caveats. And the negative VITAL-DEP prevention result is a standing rebuke to population-wide supplementation for mood. The disciplined position is narrow and defensible: correct measured deficiency; expect modest mood benefit mainly in the deficient and depressed; do not oversell.

Bottom Line

Vitamin D3 (typically 1,000–4,000 IU/day, with a fatty meal; higher loading for documented deficiency under monitoring) is a safe, cheap adjunct that corrects a deficiency-linked contributor to depression. Benefit is concentrated in patients who are deficient and/or clinically depressed; the replete and the well derive little, and the large VITAL-DEP trial found no preventive effect. Vitamin D's standout virtue is a validated status biomarker — measure 25(OH)D, then treat — which turns a hopeful supplement into a targeted intervention. A worthy adjunct held to honest, conditional expectations, not an antidepressant in its own right.

Key References

1. Okereke OI, et al. (VITAL-DEP) Effect of vitamin D3 supplementation on risk of depression and mood scores in older adults: a randomized clinical trial. JAMA. 2020.
2. Musazadeh V, et al. Vitamin D supplementation and depression: an umbrella meta-analysis. J Affect Disord. 2022.
3. Xie F, et al. Vitamin D supplementation for prevention and treatment of depression: a meta-analysis of RCTs. 2022.
4. Wang L, Su S, Liu Y. Meta-analysis of the effect of vitamin D on depression. Front Psychiatry. 2025.
5. Fu J, et al. Efficacy of vitamin D supplementation on depressive symptoms in older patients: a meta-analysis of RCTs. Front Med. 2024.
6. Cheng YC, et al. The effect of vitamin D supplement on negative emotions: a systematic review and meta-analysis. Depress Anxiety. 2020.
7. Kaviani M, et al. Effects of vitamin D supplementation on depression in adults: a systematic review and meta-analysis. 2020.
8. Eyles DW, et al. Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. J Chem Neuroanat. 2005.
9. Kaneko I, et al. Vitamin D regulates tryptophan hydroxylase 2 expression. FASEB J. 2015.
10. Anglin RES, et al. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry. 2013.
11. Jorde R, et al. Effects of vitamin D supplementation on symptoms of depression in overweight subjects. J Intern Med. 2008.
12. Vellekkatt F, Menon V. Efficacy of vitamin D supplementation in major depression: a meta-analysis of RCTs. J Postgrad Med. 2019.
13. Holick MF. Vitamin D deficiency. N Engl J Med. 2007.
14. Firth J, et al. The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review. World Psychiatry. 2019.
15. Kumar PNS, Menon V, Andrade C. Vitamin D augmentation in MDD associated with vitamin D deficiency: an RCT. J Affect Disord. 2022.